Scientists find breakthrough in AMP study for HIV prevention
Top Story
January 27, 2021
LAHORE: The global scientists have found encouraging results of latest Antibody Mediated Prevention (AMP) studies for HIV prevention, which show promise to prevent some HIV infections. The International AIDS Society (IAS) welcomed new results from two proof-of-concept AMP studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) demonstrating that infusions of the broadly neutralising monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections. The results of the AMP study, which were announced on Tuesday ahead of the opening of the 4th HIV Research for Prevention Conference (HIVR4P/Virtual), include data from more than 4,600 participants in two studies that enrolled HIV-negative men and transgender people who have sex with men in the US, Brazil and Peru (HVTN 704/HPTN 085) and HIV-negative cisgender women in sub-Saharan Africa (HVTN 703/HPTN 081).
HIV antibody trial results offer proof of concept
Outcome of AMP shows feasibility of developing potent antibody combinations to block HIV March 17, 2021 • By Sabin Russell / Fred Hutch News Service Dr. Larry Corey, former president and director of Fred Hutchinson Cancer Research Center, was protocol chair of the Antibody Mediated Prevention trials and reported first results prior to the online HIV Research for Prevention scientific conference, which opened on Jan. 27. Photo by Robert Hood / Fred Hutch News Service
Editor s note: The story below was originally published on Jan. 26, 2021, upon release of the AMP results prior to an international HIV prevention conference. Details of the paired AMP trials have now been published in the March 18, 2021 edition of the
Antibody infusions prevent acquisition of some HIV strains
An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studies, the Phase 2b trials are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The studies are being conducted jointly by the HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN).
While currently available HIV treatment and prevention tools have greatly reduced transmission of the virus, there remains a need for long-acting HIV prevention strategies that are acceptable and desirable to people from diverse communities worldwide. Broadly neutralizing antibodies (bNAbs), which
Wednesday, 27 January 2021, 7:57 am
Results of the Antibody Mediated Prevention (AMP) studies
to be presented at the IAS HIV Research for Prevention
(HIVR4P // Virtual) conference.
Tuesday, 26
January, 2021 (Geneva, Switzerland) IAS – the
International AIDS Society – welcomes new results from two
proof-of-concept studies (HVTN 704/HPTN 085 and HVTN
703/HPTN 081- the AMP Studies) demonstrating that infusions
of the broadly neutralizing monoclonal HIV antibody (bNAb)
VRC01 can prevent some HIV infections.
The AMP results include
data from more than 4,600 participants in two studies that
enrolled HIV-negative men and transgender people who have
sex with men in the U.S., Brazil and Peru (HVTN 704/HPTN
Results will inform development of long-acting antibody-based HIV prevention tools.
Scanning electromicrograph of an HIV-infected T cell. NIAID
An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to that antibody, but did not significantly reduce overall HIV acquisition after 80 weeks among participants in two multinational clinical trials. Known as the Antibody-Mediated Prevention (AMP) Studies, the Phase 2b trials are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The studies are being conducted jointly by the HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN).